N° Verde Prenotazioni (rete fissa) 800.638638 | 02 99.95.99 (da cellulare)

Abstract Patient-Device interaction monitoring and optimisation in cardiogenic shock patients

The project entails the development of a detailed protocolized approach from optimal MCS configuration according to patient's individual phenotype and shock profile, focusing on the post-implant management in critical care settings to individualize patient-device interaction and prevent complications.

The overall project will entail 3 phases:

1° phase - current (January 2024- May 2025)

  • Analysis of the completed pilot protocol (30 patients) performed in Pavia testing feasibility and reproducibility of the standard daily invasive and non-invasive
    multiorgan ultrasound) monitoring of CS patients on MCS
  • Spread of cross-sectional investigator-based survey on MCS management through ESC ACVC -- ACC research networks

2° phase - during grant period at NYU (September 2025- July 2026)

  • Prospective data collection at New York University Langone NYU enrolling all comer CS to test the higher
    accuracy of the comprehensive invasive and non-invasive monitoring protocol for the early identification of organ
    failure and optimization of patient-device interaction. 

3° phase (after the grant)

  • Develop a clinical protocol integrating invasive and
    non-invasive monitoring as standard of care addressing prompt identification of organ involvement at early CS stage. This will be extended to the NYU spoke hospitals
    (11centers) to guide the initial management of CS patients and implement the quick centralization through the hub- spoke network
  • Development of results through scientific publication and educational materials (workshop-lectures- publication series of "how to")to provide training and teach the MCS monitoring protocols
  • Validation of the protocol in a multinational registry to demonstrate the applicability and impact in patient care, outcomes and quality metrics.


    Partake in ongoing research project that has been
    developed in collaboration between Abiomed and at AHA registry about vascular complication in MCS
     

Ultimo aggiornamento: 14/01/2026